Amarin Corporation announced the publication of new data in the Journal of the American Heart Association, detailing a post-hoc analysis from the REDUCE-IT study, which found that Icosapent Ethyl ...

Icosapent ethyl is a prescription-grade derivative of the omega-3 fatty acid eicosapentaenoic acid, a component of fish oil. Icosapent ethyl may be used for the management of severe ...

In draft guidance, the health technology assessment (HTA) organisation has recommended Vazkepa (icosapent ethyl) as a treatment option for adult patients with high-risk cardiovascular disease and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk ...

Icosapent Ethyl is a synthetic derivate of the omega-3 fatty acid eicosapentaenoic acid (EPA), prescribed as an adjunct to diet to reduce hypertriglyceridemia in adults.

Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible Patients-- -- Effective 1 April 2025, Austrian ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth ...

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...

The data focus on the mechanistic activities of eicosapentaenoic acid (EPA), the active ingredient in Amarin’s icosapent ethyl product, VASCEPA/VAZKEPA, which is used to reduce cardiovascular ...